2025-02-19 - Analysis Report
## UnitedHealth Group Inc. (UNH) Stock Review

**0. Key Figures & Initial Analysis:**

UNH (UnitedHealth Group Inc.) is a diversified healthcare company offering a range of products and services.  The provided data suggests a strong historical performance relative to the S&P 500 (VOO), though recent trends show some weakening.  We will analyze this further below.


**1. Performance vs. S&P 500 (VOO):**

* **UNH Cumulative Return:** 140.28%
* **VOO Cumulative Return:** 121.84%
* **Return Difference:** 18.4%  (16.2% relative to historical range)

UNH has significantly outperformed the S&P 500 over the measured period.  The relative divergence suggests UNH's performance is currently in the upper portion of its historical performance range relative to VOO.  However, it's crucial to note that past performance is not indicative of future results.

**Alpha & Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 58.0% | 1.8% | 30.0% | 0.1 | 182.9 |
| 2016-2018  | 66.0% | 10.5% | 47.0% | 0.1 | 209.5 |
| 2017-2019  | 52.0% | 10.5% | 21.0% | 0.3 | 251.4 |
| 2018-2020  | 32.0% | 10.5% | 5.0% | 0.3 | 304.8 |
| 2019-2021  | 96.0% | 9.4% | 26.0% | 0.3 | 442.6 |
| 2020-2022  | 102.0% | 5.5% | 93.0% | 0.3 | 473.3 |
| 2021-2023  | 60.0% | 5.5% | 37.0% | 0.3 | 477.0 |
| 2022-2024  | -24.0% | 16.6% | -57.0% | 0.3 | 465.5 |
| 2023-2025  | -14.0% | 16.6% | -77.0% | 0.2 | 481.8 |

The high CAGR (Compound Annual Growth Rate) in most years indicates strong historical growth.  However, the recent negative CAGR and increasing MDD (Maximum Drawdown) are concerning.  The Alpha values suggest significant outperformance in some periods, but this has recently turned negative. The relatively low Beta suggests less volatility than the overall market.

**2. Recent Price Movements:**

* **Closing Price:** $523.51
* **5-Day Moving Average:** $529.88
* **20-Day Moving Average:** $533.44
* **60-Day Moving Average:** $540.37

The price is currently below all three moving averages, suggesting a possible downward trend.

**3. Technical Indicators:**

* **RSI:** 35.21 (Potentially oversold, but needs confirmation)
* **PPO:** -0.2462 (Negative, indicating bearish momentum)
* **20-Day Relative Divergence Change:** -3.5% (Short-term downward trend)
* **Expected Return:** 411.5% (Long-term expected return relative to S&P 500)

The RSI suggests the stock may be oversold, but further analysis is required. The negative PPO confirms bearish momentum. The expected return is exceptionally high and needs further investigation to validate its source and methodology.

**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue        |
|------------|--------|----------------|
| 2024-11-04 | 6.56   | 100.82 B$      |
| 2024-08-09 | 4.58   | 98.86 B$      |
| 2024-05-09 | -1.53  | 99.80 B$      |
| 2023-11-06 | 6.31   | 92.36 B$      |
| 2024-11-04 | 6.31   | 92.36 B$      | *(Duplicate Entry?)*


Revenue shows consistent growth, although there's a significant negative EPS in Q2 2024 that needs explanation. The duplicate entry for November 2024 needs clarification.  Further investigation into these figures and the potential for data errors is necessary.

**5. Financial Information:**

The absence of "Total Revenue" and "Gross Profit" data prevents a comprehensive financial analysis. This data is crucial for a proper assessment of the company's financial health.

**6. Overall Analysis:**

UNH has historically outperformed the S&P 500, but recent performance indicators show a weakening trend.  The negative CAGR, increasing MDD, negative PPO, and price below moving averages suggest a bearish short-term outlook.  However, the RSI suggests potential oversold conditions.  The exceptionally high projected long-term return needs further scrutiny.  The missing financial data and inconsistencies in the earnings data hinder a complete and accurate assessment.  Further investigation into the earnings report, financial statements, and the methodology behind the expected return is crucial before making any investment decisions.
